Stephen Cartt - Brooklyn Immunotherapeuti Director

BTX
 Stock
  

USD 0.53  0.02  3.64%   

  Director
Mr. Stephen L. Cartt is a Director of BioTime Inc. effective November 2014. Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals Inc. from February 2012 until August 2014 when the company was acquired by Mallinckrodt plc. Mr. Cartt served as Chief Operating Officer of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc on an interim basis following the merger with Questcor from August 2014 until October 2014. Mr. Cartt joined Questcor as Executive Vice President Corporationrationrate Development during March 2005. He was later appointed Chief Business Officer before being appointed Chief Operating Officer. Mr. Cartt was a private consultant from August 2002 until March 2005. From March 2000 through August 2002 Mr. Cartt was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Prior to that Mr. Cartt held a variety of RD and Commercial positions at ALZA Corporationrationration during the period July 1985 to March 2000
Age: 51  Director Since 2014  MBA    
212 582 1199  https://www.brooklynitx.com
Cartt holds a B.S. degree from the University of California at Davis in Biochemistry, and an M.B.A. from Santa Clara University.

Brooklyn Immunotherapeuti Management Efficiency

Brooklyn Immunotherapeuti has Return on Asset of (74.2) % which means that on every $100 spent on asset, it lost $74.2. This is way below average. Brooklyn Immunotherapeuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -24.25 in 2022. Return on Average Assets is likely to drop to -3.2 in 2022. Brooklyn Immunotherapeuti Current Assets are fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Assets of 18.77 Million in 2021. Goodwill and Intangible Assets is likely to rise to about 2.1 M in 2022, whereas Total Assets are likely to drop slightly above 26.9 M in 2022.
The company has 2.72 M in debt with debt to equity (D/E) ratio of 0.42, which is OK given its current industry classification. Brooklyn Immunotherapeuti has a current ratio of 5.0, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brooklyn Immunotherapeuti until it has trouble settling it off, either with new capital or with free cash flow. So, Brooklyn Immunotherapeuti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brooklyn Immunotherapeuti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brooklyn to invest in growth at high rates of return. When we think about Brooklyn Immunotherapeuti's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

James CashGeneral Electric
N/A
Edward GardenGeneral Electric
2017
James TischGeneral Electric
2010
Catherine LesjakGeneral Electric
2019
Andrea JungGeneral Electric
1998
Robert LaneGeneral Electric
2005
Risa LavizzoMoureyGeneral Electric
2017
John BrennanGeneral Electric
2014
Marijn DekkersGeneral Electric
2012
Douglas WarnerGeneral Electric
N/A
James RohrGeneral Electric
2013
Mary SchapiroGeneral Electric
2013
Francisco DSouzaGeneral Electric
2013
Paula ReynoldsGeneral Electric
2018
Lowell McAdamGeneral Electric
2016
Peter HenryGeneral Electric
2016
Robert SwieringaGeneral Electric
N/A
Leslie SeidmanGeneral Electric
2018
Sebastien BazinGeneral Electric
2016
Thomas HortonGeneral Electric
2018
James MulvaGeneral Electric
2008
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people. Brooklyn Immunotherapeutics (BTX) is traded on NYSEMKT Exchange in USA. It is located in 10355 Science Center Drive and employs 10 people. Brooklyn Immunotherapeutics was previously known as BROOKLYN IMMUNOTHERAPEUTICS INC and was traded on NYSEMKT Exchange under the symbol NTN. Brooklyn Immunotherapeuti is listed under Pharmaceutical Products category by Fama And French industry classification.

Brooklyn Immunotherapeuti Leadership Team

Elected by the shareholders, the Brooklyn Immunotherapeuti's board of directors comprises two types of representatives: Brooklyn Immunotherapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brooklyn. The board's role is to monitor Brooklyn Immunotherapeuti's management team and ensure that shareholders' interests are well served. Brooklyn Immunotherapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brooklyn Immunotherapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Mulroy, Director
David Schlachet, Director
Stanislaw Pargiela, Member of the Supervisory Board
Michael West, Co-CEO and President and Director
Chase Leavitt, General Counsel and Corporate Secretary
Matt Haines, IR Contact Officer
Don Bailey, Director
Brandi Roberts, CFO, Senior Vice President - Finance
Stephen Cartt, Director
Artur Maczynski, Vice Chairman of the Supervisory Board
Lech Pasturczak, Vice Chairman of the Supervisory Board
Edward Wirth, Other
Stephen Farrell, Independent Director
Tomasz Gierczynski, Chairman of the Management Board
Alfred Kingsley, Chairman of the Board
Judith Segall, VP of Admin., Secretary and Director
Stephana Patton, General Counsel
Deborah Andrews, Director
Dorota Walkiewicz, Member of the Management Board for Administration and Organization
Blazej Wisniewski, Member of the Management Board for Finance, Chief Accounting Officer
David Nakasone, Director - Investor Relations
Jim Knight, Senior Vice President-Head of Corporate Development
Russell Skibsted, CFO
Brian Culley, President CEO, Director
Heinz Jammers, Member of the Supervisory Board
Gary Hogge, Senior Vice President of Clinical & Medical Affairs
Andrzej Pargiela, Secretary of the Supervisory Board
Pedro Lichtinger, CEO of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics Inc
Neal Bradsher, Independent Director
Angus Russell, Director
Aditya Mohanty, Co-CEO
Cavan Redmond, Independent Director
Konrad Kosierkiewicz, Chairman of the Supervisory Board

Brooklyn Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brooklyn Immunotherapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.